Drug Trial Radar · NCT06973720
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
268
Actual
Start
Apr 7, 2025
Primary completion
Dec 16, 2025
Study completion Oct 19, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to test the weight loss effects, safety, and tolerability of multiple monthly doses of MET097 after 12 weekly doses, compared to placebo. Participants are eligible if they have overweight or obesity and do not have type 2 diabetes.
Conditions
- Obesity
- Overweight or Obesity
Interventions
MET097Drug
For subcutaneous administration.
PlaceboDrug
Sterile 0.9% (w/v) saline for subcutaneous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in body weight at Week 28Time frame: Baseline (Week 0) through Week 28 (Day 197)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Centers of America
Hollywood, Florida
ForCare Clinical Research
Tampa, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
CenExel iResearch, LLC
Decatur, Georgia
CenExel iResearch, LLC
Savannah, Georgia
Hassman Research Institute
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.